In Recommending Flibanserin Approval, FDA Panelists Urge Alcohol Contraindication
Panel’s vote to approve Sprout’s female sexual dysfunction drug is conditioned on a REMS and possible contraindication with alcohol use; questions about drug’s date rape potential, breast cancer finding in mice addressed.
You may also be interested in...
In sharp disagreement, FDA says postmarketing trial shows risk of taking alcohol with the female sexual dysfunction drug; Sprout will appeal agency's decision.
Addyi ingredient found in Organic Herbal Supply products; FDA, Australia recognize food safety systems as comparable; and researchers show B vitamins could have a role in reducing the impact of air pollution on the epigenome.
Draft guidance says 'associated distress' may replace number of satisfying sexual events as a co-primary efficacy endpoint.